COVID-19 Vaccine Related Topics 
Bill of Health
NOVEMBER 8, 2022
In June 2022, after almost two years of debate over a potential COVID-19 vaccine patent waiver, the World Trade Organization adopted the Ministerial Decision on the TRIPS Agreement (“WTO Decision”), which provided for a partial waiver of intellectual property rights. By Sarah Gabriele. appeared first on Bill of Health.
Healthcare It News
SEPTEMBER 10, 2021
Prior to the pandemic there were no platforms designed for mass patient registration, complex scheduling and communication, let alone platforms that managed all the specific information required for COVID-19 vaccinations, said Jonathan Golden, Georgia deputy area director of CORE. " Twitter: @SiwickiHealthIT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
JANUARY 12, 2023
government committed more than one billion dollars to Moderna for development of its COVID-19 vaccines. Moderna has since made over $30 billion in COVID-19 vaccine sales. The post COVID-19 Vaccine Patent Infringement? Indeed, as made public, the U.S.
Healthcare Dive
FEBRUARY 8, 2022
The company estimated revenue from its COVID-19 vaccine and new antiviral pill Paxlovid will total $54 billion this year.
Healthcare Dive
AUGUST 31, 2022
The commercial market for COVID-19 vaccinations could be similar to that for seasonal flu shots and other vaccines, the department said.
Healthcare It News
OCTOBER 22, 2021
As communities across the nation seek new ways to bring COVID-19 vaccination rates up to levels that can more effectively mitigate the spread of variants, they are looking for new and better ways to reach those who are just hesitant, undecided or unaware of how to get vaccinated.
Electronic Health Reporter
OCTOBER 7, 2021
The American Medical Association (AMA) announced that the Current Procedural Terminology (CPT) code set has been updated by the CPT Editorial Panel to include vaccine and administration codes for pediatric doses of the COVID-19 vaccine developed […].
Expert insights. Personalized for you.
311 
Let's personalize your content